| Name | Breeze Care Center |
|---|---|
| Location | 1755 18th St, Sarasota, Florida |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 101 |
| Occupancy Rate | 78.91% |
| Medicare ID (CCN) | 105774 |
| Legal Business Name | Legal Business Name Not Available |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1285798082 |
| Organization Name | J H FLOYD SUNSHINE MANOR INC |
| Address | 1755 18th St, Sarasota, FL 34234 |
| Phone Number | 941-955-4915 |
News Archive
Among scientists specializing in the area, the mechanisms behind the signaling function of the Hedgehog (Hh) receptor pathway remain a mystery. Xiaoyen Zheng, Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, who recently received a $1.7 million grant from the National Institutes of Health and National Institute of General Medical Sciences, is determined to learn more about the Hh pathway.
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
Better known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression. But ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.
› Verified 6 days ago
| NPI Number | 1366228132 |
| Organization Name | 18TH ST SARASOTA, OPCO LLC |
| Address | 1755 18th St, Sarasota, FL 34234 |
| Phone Number | 718-916-1443 |
News Archive
Among scientists specializing in the area, the mechanisms behind the signaling function of the Hedgehog (Hh) receptor pathway remain a mystery. Xiaoyen Zheng, Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, who recently received a $1.7 million grant from the National Institutes of Health and National Institute of General Medical Sciences, is determined to learn more about the Hh pathway.
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
Better known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression. But ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.
› Verified 6 days ago
| NPI Number | 1598045320 |
| Organization Name | BGI RETIREMENT LLC |
| Doing Business As | CROSSBREEZE CARE CENTER |
| Address | 1755 18th St, Sarasota, FL 34234 |
| Phone Number | 941-955-4915 |
News Archive
Among scientists specializing in the area, the mechanisms behind the signaling function of the Hedgehog (Hh) receptor pathway remain a mystery. Xiaoyen Zheng, Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, who recently received a $1.7 million grant from the National Institutes of Health and National Institute of General Medical Sciences, is determined to learn more about the Hh pathway.
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
Better known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression. But ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.
› Verified 6 days ago
| NPI Number | 1790396489 |
| Organization Name | CENTER FOR AGING AND REHABILITATION OF SARASOTA INC |
| Doing Business As | BREEZE CARE CENTER |
| Address | 1755 18th St, Sarasota, FL 34234 |
| Phone Number | 419-554-9159 |
News Archive
Among scientists specializing in the area, the mechanisms behind the signaling function of the Hedgehog (Hh) receptor pathway remain a mystery. Xiaoyen Zheng, Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, who recently received a $1.7 million grant from the National Institutes of Health and National Institute of General Medical Sciences, is determined to learn more about the Hh pathway.
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
Better known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression. But ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.
› Verified 6 days ago
| NPI Number | 1871946194 |
| Organization Name | 1755 GOLDEN LLC |
| Doing Business As | CROSSBREEZE CARE CENTER |
| Address | 1755 18th St, Sarasota, FL 34234 |
| Phone Number | 941-955-4915 |
News Archive
Among scientists specializing in the area, the mechanisms behind the signaling function of the Hedgehog (Hh) receptor pathway remain a mystery. Xiaoyen Zheng, Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, who recently received a $1.7 million grant from the National Institutes of Health and National Institute of General Medical Sciences, is determined to learn more about the Hh pathway.
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
Better known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression. But ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Among scientists specializing in the area, the mechanisms behind the signaling function of the Hedgehog (Hh) receptor pathway remain a mystery. Xiaoyen Zheng, Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, who recently received a $1.7 million grant from the National Institutes of Health and National Institute of General Medical Sciences, is determined to learn more about the Hh pathway.
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
Better known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression. But ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20.62 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.73 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 18.52 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.75 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.69 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.68 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.89 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.37 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 7.41 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.26 | 83.88 |